FT. MYERS, FL/ACCESSWIRE/May 16, 2022/ NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”)a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Lynn Tetrault, Esq., the current Executive Chairman and Senior Managing Director, as Chairman of the Board and Interim CEO effective May 12, 2022.

Ms. Tetrault has served as executive chair since March, when the company’s chief executive agreed to step down. Ms. Tetrault oversaw the interim CEO’s office to ensure continuity of leadership and operational management of the company while the board conducted a search for the company’s permanent CEO.

“Lynn’s leadership has been exceptional during this difficult time, and we have complete confidence in her as interim CEO of the company until we find the perfect candidate for the role. With Lynn as CEO interim, we can streamline the management structure as we continue to execute our operating plans and create long-term value for all of our shareholders. The external search for a new CEO is progressing well and meets our expectations,” said Michael Kelly, Lead Independent Director.

Ms. Tetrault, who has served on the Board since June 2015, served as Lead Independent Director from 2020 to 2021 and was appointed Non-Executive Chairman in October 2021. Previously, Ms. Tetrault held various senior positions at AstraZeneca PLC from 1993 to 2014 , including Executive Vice President of Human Resources and Corporate Affairs from 2007 to 2014. Ms. Tetrault is also a non-executive director of Rhythm Pharmaceuticals. Ms. Tetrault holds an undergraduate degree from Princeton University and a JD from the University of Virginia School of Law.

The company also announced that Chief Strategy and Business Development Officer Douglas Brown will be leaving the company on May 27 to pursue other interests. Chief Financial Officer William Bonello and Chief Cultural Officer Jennifer Balliet will continue in their current roles.

“We are privileged to have a deep and experienced team at NeoGenomics. Over the past few months, I have been able to work more closely with the team and am impressed with their capability, commitment and strong company culture,” said Lynn Tetrault, Board Chair and Chief From NeoGenomics Interim CEO “Our leadership team has worked tirelessly during this early transition phase and I cannot thank them enough for their efforts. I am delighted to continue working with Bill, Jennifer and the entire management team. as we continue to execute our short-term operational plans. I would also like to thank Doug for his contributions to the company and wish him the best for the future.

About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetic testing and information services, providing one of the world’s most comprehensive oncology-focused test menus for physicians to help diagnose and treat cancer. cancer. The Company’s Pharmaceutical Services Division serves pharmaceutical clients in clinical trials and drug development.

NeoGenomics is committed to connecting patients with life-changing therapies and trials. We believe that together, with our partners, we can help cancer patients today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to all relevant data protection laws, provides transparency and choice to patients regarding the processing and use of their data through our Notice of Privacy Practices, and has invested in state-of-the-art technology to ensure the security of the data we store. always.

Based in Fort Myers, Florida, NeoGenomics operates CAP-accredited and CLIA-certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, CA; Research Triangle Park, North Carolina; Houston, TX; Atlanta, Georgia; Nashville, TN; and Phoenix, Arizona; and CAP accredited laboratories in Cambridge, UK; Rolle, Switzerland; and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical companies, integrated service delivery networks and managed care organizations in the United States, as well as pharmaceutical companies in Europe and Asia . We regularly post information that may be important to our investors on our website at www.neogenomics.com.

Forward-looking statements

This press release contains forward-looking statements. These forward-looking statements can generally be identified by the use of words such as “anticipate”, “expect”, “plan”, “could”, “could”, “could”, “will”, “believe”, “estimate”, “forecast”, “goal”, “project”, “direction”, “plan”, “potential” and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address a variety of topics, including statements regarding improved operating efficiencies, return to profitable growth and its ongoing executive search process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by Applicable risks and uncertainties include, among others, the Company’s ability to identify and implement appropriate financial and operational initiatives to improve performance, identify and recruit leadership candidates, continue to win new customers, respond to the effects of the COVID outbreak -19, propose new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10 -K for l year ended December 31, 2021 filed with the SEC on February 25, 2022 together with other information previously filed with the SEC.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. We encourage you to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements contained in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. . Our business is subject to substantial risks and uncertainties, including those mentioned above. Investors, potential investors and others should pay particular attention to these risks and uncertainties.

For more information, please contact:

Charlie Eidson
Director, Investor Relations and Corporate Development
Tel: 239.768.0600 x2726
M: 952.221.8816
[email protected]

THE SOURCE: NeoGenomics, Inc.

See the source version on accesswire.com:
https://www.accesswire.com/701453/NeoGenomics-Appoints-Lynn-Tetrault-Interim-CEO